生信分析、meta分析、数据挖掘
TCGA、GEO、SEER、Oncomine

这本近三年来一直五六分的SCI,明年或将不低于6分


2019年6月科睿唯安发布的期刊引证报告中,SAGE期刊呈现了良好的增长趋势。今天,我们来看看这本SCI期刊:Therapeutic Advances in Medical Oncology (TAM)

Therapeutic Advances in Medical Oncology (TAM)是经过同行评审的开放获取期刊,出版癌症以及治疗领域的前沿探索和创新研究,主要受众群体为全球肿瘤领域及相关学科的临床医生和研究人员。该刊最新影响因子(JCR2018)为5.670

The journal has an Impact Factor of 5.670 and is ranked 39 out 229 Journals in the Oncology category. 

 

Therapeutic Advances in Medical Oncology (TAM) is a peer-reviewed open access journal which focuses on pioneering efforts and innovative studies in the medical treatment of cancer.

Therapeutic Advances in Medical Oncology delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of cancer. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in medical oncology, providing an online forum for rapid dissemination of recent research and perspectives in this area.

The editors welcome original research articles across all areas of oncology.

The journal publishes original research articles and review articles primarily. Original research manuscripts may include laboratory, animal or human/clinical studies – all phases. Letters to the Editor and Case Reports will also be considered.


Authors will enjoy:

  • Authors will enjoy:

  • Impact Factor: 5.670
  • Ranked 39 out of 229 in Oncology 
  • Listed in PubMed, SCIE, PMC, Scopus and DOAJ
  • International expert Editorial Board and panel of Associate Editors
  • Rigorous and fast peer review
  • Rapid online publication (~3 weeks after article acceptance)

  • 期刊主页:

  • https://journals.sagepub.com/home/tama

长按扫描上方二维码

访问TAM期刊首页,了解更多详情


近三年来,Therapeutic Advances in Medical Oncology (TAM)的影响因子一直都在五六分时影响因子计算发现,2019年8月16日,3.57按照往年经验,在2020年6月份公布的IF中,它或将不低于6分 !但因为距离明年6月份时间还很长,因此具体IF分值,年底的预测会准确一些!


有5+/6+分以上发表要求的,来看看这个SCI期刊吧!

如何选择SCI期刊,也是一门技巧。“51选刊”应此而建,目的主要是帮助大家选择拟投稿的SCI期刊!51选刊”目前已经开通了:SCI期刊自引率版面费是否属于OA期刊、年发文量投稿难度投稿网址、中科院分区等功能!欢迎大家关注!

扫描二维码即可关注“51选刊” (ID:  woyaoxuankan)!

赞(0) 打赏
未经允许不得转载:医学SCI科研之家 » 这本近三年来一直五六分的SCI,明年或将不低于6分
分享到: 更多 (0)

评论 抢沙发

评论审核已启用。您的评论可能需要一段时间后才能被显示。

  • 昵称 (必填)
  • 邮箱 (必填)
  • 网址

meta分析、生信分析

meta、生信交流群综合科研交流群